Malta - English - Medicines Authority

bio products laboratory limited - factor viii, human; von willebrand factor, human - powder and solvent for solution for injection - factor viii, human 250 iu; von willebrand factor, human 430 iu - antihemorrhagics

Malta - English - Medicines Authority

bio products laboratory limited - factor viii, human; von willebrand factor, human - powder and solvent for solution for injection - factor viii, human 500 iu; von willebrand factor, human 860 iu - antihemorrhagics

Malta - English - Medicines Authority

bio products laboratory limited - factor viii, human; von willebrand factor, human - powder and solvent for solution for injection - factor viii, human 1000 iu; von willebrand factor, human 1720 iu - antihemorrhagics

Canada - English - Health Canada

baxter ag - total protein; factor xiii; fibrinogen (human); plasmafibronectin (cig); plasminogen; aprotinin (bovine); thrombin (human); thrombin (human); calcium chloride - kit - 260mg; 100unit; 220mg; 18mg; 240mcg; 6000kiu; 8unit; 1000unit; 80mcmol - total protein 260mg; factor xiii 100unit; fibrinogen (human) 220mg; plasmafibronectin (cig) 18mg; plasminogen 240mcg; aprotinin (bovine) 6000kiu; thrombin (human) 8unit; thrombin (human) 1000unit; calcium chloride 80mcmol - hemostatics

Canada - English - Health Canada

takeda canada inc - antithrombin iii (human) - kit - 1100unit - antithrombin iii (human) 1100unit - direct thrombin inhibitors

Canada - English - Health Canada

takeda canada inc - antithrombin iii (human) - kit - 550unit - antithrombin iii (human) 550unit - direct thrombin inhibitors

United States - English - NLM (National Library of Medicine)

grifols usa, llc - factor ix complex (unii: fw411qxd5m) (factor ix complex - unii:fw411qxd5m) - factor ix complex 500 [iu] in 5 ml - profilnine, factor ix complex, is indicated for the prevention and control of bleeding in patients with factor ix deficiency (hemophilia b). profilnine contains non-therapeutic levels of factor vii and is not indicated for use in the treatment of factor vii deficiency. none known.

United States - English - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k), human thrombin (unii: 6k15abl77g) (human thrombin - unii:6k15abl77g) - fibrinogen 90 [iu] in 1 ml - tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in surgeries involving cardiopulmonary bypass and treatment of blunt or penetrating splenic injuries when control of bleeding by conventional surgical techniques, including suture, ligature, and cautery, is ineffective or impractical. tisseel is a hemostatic agent that may be used in fully heparinized patients undergoing cardiopulmonary bypass. tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, may result in life-threatening thromboembolic events, and may increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients (see warnings and precautions, use in cardiopulmonary surgery (5.3

United States - English - NLM (National Library of Medicine)

baxalta us inc. - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - fibrinogen 90 mg in 1 ml - tisseel is a fibrin sealant indicated for use as an adjunct to hemostasis in surgeries involving cardiopulmonary bypass and treatment of blunt or penetrating splenic injuries when control of bleeding by conventional surgical techniques, including suture, ligature, and cautery, is ineffective or impractical. tisseel is a hemostatic agent that may be used in fully heparinized patients undergoing cardiopulmonary bypass. tisseel is a fibrin sealant indicated as an adjunct to standard surgical techniques (such as suture and ligature) to prevent leakage from colonic anastomoses following the reversal of temporary colostomies. do not inject tisseel directly into the circulatory system or into highly vascularized tissue. intravascular application of tisseel can lead to intravascular coagulation, may result in life-threatening thromboembolic events, and may increase the likelihood and severity of acute hypersensitivity reactions in susceptible patients (see warnings and precautions, use in cardiopulmonary surgery (5.3

United States - English - NLM (National Library of Medicine)

ethicon inc - fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - evicel® fibrin sealant (human) is indicated as an adjunct to hemostasis for use in patients undergoing surgery when control of bleeding by standard surgical techniques (such as suture, ligature, or cautery) is ineffective or impractical. do not use evicel®: - directly into the circulatory system. intravascular application of evicel® may result in life-threatening thromboembolic events [see warnings and precautions, (5.1) and adverse reactions, (6.2)]. - in individuals known to have anaphylactic or severe systemic reaction to human blood products [see adverse reactions (6.2)]. - for brisk arterial bleeding. - for spraying in endoscopic or laparoscopic procedures in those instances where the minimum recommended distance from the applicator tip to the target site cannot be ensured. [see dosage and administration (2.3)]. risk summary there are no data with evicel® use in pregnant women to inform a drug-associated risk. animal reproduction studies have not been conducted with evicel® . it is not known whether